Company profile
Precigen, Inc.
NASDAQ: PGEN · Healthcare · Biotechnology
#636 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
44DFH 28DQ 59GM 50SS 72
v0.1 · 65/100 weight · provisional
↑ market scale, revenue growth (YoY) · ↓ return on equity, net margin
Methodology →Revenue TTM
$31.6M
Rev growth YoY (TTM)
+652.1%
Net income (FY)
-$250.6M
Employees
160
as of 2026-08-09
Market cap
$2.6B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$9.7M$9.7M2025
Net income-$250.6M-$250.6M2025
Operating income-$110.5M-$110.5M2025
Total assets$155.5M$155.5M2025
Liabilities$134.6M$134.6M2025
Equity$20.9M$20.9M2025
Revenue trend
FY2020 – FY2025 · USD
FY20
FY20
FY20
FY21
FY22
FY25
FY25
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Exemplar100%
By geography
Not disclosed.
The read
What is Precigen, Inc.’s revenue?
Precigen, Inc. booked $9.7M in FY2025 revenue, growing 147% year over year — faster than most Healthcare companies we track, at a -2588.2% net margin.
Peers · Healthcare
Stablecoin Development Corp.44DTaysha Gene Therapies, Inc.48DCalithera Biosciences, Inc.——Delivra Health Brands Inc.55CYulong Eco-Materials Limited——ThermoGenesis Holdings, Inc.——Neighbors
Montgomery →Key facts
CEOHelen Sabzevari
SectorHealthcare
IndustryBiotechnology
HeadquartersGermantown, MD
ExchangeNASDAQ: PGEN
Employees160
IPO date2013-08-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.